Chimeric antibody with specificity to human B cell surface antigen

An immunoassay method for the detection of an antigen comprising the Bp35 polypeptide normally expressed on the surface of B cells, said method comprising contacting a chimeric antibody with a sample to be tested for the presence of said antigen, and detecting a detectable label as an indication of the presence of said antigen, wherein said chimeric antibody comprises two light chains and two heavy chains, each of said chains comprising a variable region and a human constant region, said chimeric antibody being produced in a eukaryotic host and having specificity for the antigen bound by the antibody produced by hybridoma HB9303 as deposited with the ATCC, wherein said chimeric antibody, as produced by said host, is capable of mediating antibody-dependent cellular cytotoxicity or complement-dependent cytolysis.

An in vivo or in vitro imaging method to detect an antigen comprising the Bp35 polypeptide normally expressed on the surface of B cells, said method comprising contacting said antigen with a detectably labelled chimeric antibody and detecting said detectable label as an indication of the presence of said antigen, wherein said chimeric antibody comprises two light chains and two heavy chains, each of said chains comprising a variable region and a human constant region, said chimeric antibody being produced in a eukaryotic host and having specificity for the antigen bound by the antibody produced by hybridoma HB9303 as deposited with the ATCC, wherein said chimeric antibody, as produced by said host, is capable of mediating antibody-dependent cellular cytotoxicity or complement-dependent cytolysis.

A method of killing cells beating the antigen bound by the antibody produced by hybridoma HB9303 as deposited with the ATCC, which comprises:

• (a) contacting said cells with a chimeric antibody;
• (b) allowing said killing to occur, wherein said killing occurs by antibody-dependent cellular cytotoxicity of complement-mediated lysis of said cells,
• wherein said chimeric antibody comprises two light chains and two heavy chains, each of said chains comprising a variable region and a human constant region, said chimeric antibody being produced in a eukaryotic host and having specificity for the antigen bound by the antibody produced by hybridoma HB9303 as deposited with the ATCC, wherein said chimeric antibody, as produced by said host, is capable of mediating antibody-dependent cellular cytotoxicity or complement-dependent cytolysis.

A method of killing or modulating cells bearing the antigen bound by the antibody produced by hybridoma HB9303 as deposited with the ATCC, which comprises:

• contacting said cells with a chimeric antibody coupled to a drug, toxin, immunomodulator, peptide effector, or isotope,
• wherein said chimeric antibody comprises two light chains and two heavy chains, each of said chains comprising a variable region and a human constant region, said chimeric antibody being produced in a eukaryotic host and having specificity for the antigen bound by the hybridoma HB9303 as deposited with the ATCC, wherein said chimeric antibody, as produced by said host, is capable of mediating antibody dependent-cellular mediated cytotoxicity or complement dependent cytolysis.